Characterization of the acute endocrine actions of (-)-11-hydroxy-Δ8-tetrahydrocannabinol-dimethylheptyl (HU-210), a potent synthetic cannabinoid in rats

European Journal of Pharmacology

Volumn 344, Issue 1, 1998, Pages 77-86

  Martín Calderón, Jose Luis ^a   Muñoz, Raúl M ^a   Villanúa, María Angeles ^a   Del Arco, Ignacio ^a   Moreno, Jose Luis ^a   De Fonseca, Fernando Rodríguez ^a   Navarro, Miguel ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Cannnbinoid; Corticosterone; Dopamine; Estrous cycle; Hypothalamus; Pituitary hormone

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; CANNABINOID; CANNABINOID RECEPTOR; DEXANABINOL;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DRUG EFFECT; ENDOCRINE FUNCTION; ESTRUS CYCLE; FOLLITROPIN BLOOD LEVEL; GROWTH HORMONE BLOOD LEVEL; HORMONE RELEASE; HYPOTHALAMUS; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; LUTEINIZING HORMONE BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RAT;

ANIMALS; CATECHOLAMINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCRINE SYSTEM; ESTRUS; FEMALE; HORMONES; HYPOTHALAMUS; MALE; RATS; RATS, WISTAR; TETRAHYDROCANNABINOL;

EID: 0032567980     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01560-4     Document Type: Article

References (43)

1. 1-tetrahydrocannabinol on the hypothalamo-pituitary-ovarian axis in the rat. Neuroendocrinology. 23:1977;31-42.
2. Ben-Jonathan N. Dopamine: A prolactin inhibiting hormone. Endocr. Rev. 6:1985;564-589.
3. 9-tetrahydrocannabinol effects on the nigrostriatal dopaminergic activity in the female rat brain. Mol. Cell. Neurosci. 3:1992;325-325.
4. 9-tetrahydrocannabinol on tuberoinfundibular dopamine activity, anterior pituitary sensitivity to dopamine and prolactin release very as a function of the estrous cycle. Neuroendocrinology. 58:1993;280-286.
5. Devane W.A., Dysarz III F.A., Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:1988;605-613.
6. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson R.G., Griffin G., Gibson D., Mandelbaum L.A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
7. Dewey W.L. Cannabinoid pharmacology. Pharmacol. Rev. 38:1986;151-178.
8. Eldridge J.C., Landfield P.W. Cannabinoid interactions with glucocorticoid receptors in rat hippocampus. Brain Res. 534:1990;135-141.
9. Esquifino A.I., Moreno M.L., Agrasal C., Villanúa M.A. Effects of cyclosporine on ovarian function in sham-operated and pituitary-grafted young female rats. Proc. Soc. Exp. Biol. Med. 208:1995;397-403.
10. 9-tetrahydrocannabinol: Changes in hypothalamic biogenic amines. Neuroendocrinol. Lett. 14:1992;349-355.
11. 1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics. Biochem. Pharmacol. 53:1997;1919-1927.
12. Gamallo A., Villanúa M.A., Trancho G., Fraile A. Stress adaptation and adrenal activity in isolated and crowded rats. Physiol. Behav. 36:1986;217-221.
13. Glass M., Dragunov M. Induction of the Korx 24 transcription factor in striosomes by a cannabinoid agonist. Neuroreport. 6:1995;241-244.
14. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA. 87:1990;1932-1936.
15. -8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor. Neuropharmacology. 29:1990;161-165.
16. Howlett A.C., Champion-Dorow T.M., McMahon I.L., Westlake T.M. The cannabinoid receptor: Biochemical and cellular properties in neuroblastoma cells. Pharmacol. Biochem. Behav. 40:1991;565-569.
17. Hughes C.L., Everett J.W., Tyrey L. Delta-9-tetrahydrocannabinol suppression of prolactin secretion in the rat: Lack of direct pituitary effect. Endocrinology. 109:1981;876-880.
18. Kitchen I., Kelly M., Turner M. Dopamine modulation of corticosterone secretion in neonatal and adult rats. J. Pharm. Pharmacol. 40:1988;580-581.
19. 9-THC): Involvement of serotoninergic and dopaminergic pathways. Endocrinology. 103:1978;452-457.
20. 1-tetrahydrocannabinol in rats. Eur. J. Pharmacol. 14:1971;89-92.
21. 8-tetrahydrocannabinol-dimethylheptyl on mice and dogs. Pharmacol. Biochem. Behav. 32:1989;661-666.
22. Mailleux P., Vanderhaeghen J.J. Distribution of neuronal cannabinoid receptor in the adult rat brain: A comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience. 48:1992;655-668.
23. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
24. Murphy, L.L., Steger, R.W., Bartke, A., 1990a. Psychoactive and non psychoactive cannabinoids and their effects on reproductive neuroendocrine parameters. In: Watson, R.R. (Ed.), Biochemistry and Physiology of Substance Abuse, vol. 2. CRC Press, Boca Raton, FL, pp. 73-93.
25. 9-tetrahydro-cannabinol, cannabidiol and cannabinol, alone and in combinations, on luteinizing hormone and prolactin release and on hypothalamic neurotransmitters in the male rat. Neuroendocrinology. 52:1990;316-321.
26. 9-Tetrahydrocannabinol antagonism of the anterior pituitary response to estradiol in immature female rats. Steroids. 56:1991;97-102.
27. 9-tetrahydrocannabinol affects behavioral and neurochemical indices of mesolimbic dopaminergic activity. Behav. Brain. Res. 5:1993;37-46.
28. Ovadia H., Wohlman A., Mechoulam R., Weidenfeld J. Characterization of the synthetic cannabinoid HU-210 in the rat. Relation to the adrenergic system and endogenous pyrogens. Neuropharmacology. 34:1995;175-180.
29. Rettori V., Wenger T., Snyder G., Dalterio S., McCann S.M. Hypothalamic action of delta-9-tetrahydrocannabinol to inhibit the release of prolactin and growth hormone in the rat. Neuroendocrinology. 47:1988;498-503.
30. Rodríguez de Fonseca F., Cebeira M., Fernández-Ruiz J.J., Navarro M., Ramos J.A. Effects of pre- and perinatal exposure to hashish extracts on the ontogeny of brain dopaminergic neurons. Neuroscience. 43:1991;713-723.
31. Rodríguez de Fonseca F.A., Fernández-Ruiz J.J., Eldridge J.C., Steger R.W., Bartke A., Murphy L.L. Effects of the exposure to delta-9-tetrahydrocannabinol on the adrenal medullary function: Evidence of an acute effect and development of tolerance in chronic treatments. Pharmacol. Biochem. Behav. 40:1991;593-598.
32. Rodríguez de Fonseca F., Ramos J.A., Bonnin A., Fernández-Ruiz J.J. Presence of cannabinoid binding sites in the brain from early postnatal ages. Neuroreport. 4:1993;135-138.
33. Rodríguez de Fonseca F.A., Cebeira M., Ramos J.A., Martín M., Fernández-Ruiz J.J. Cannabinoid receptors in rat brain areas: Sexual differences, fluctuations during estrous cycle and changes after gonadectomy and sex steroid replacement. Life Sciences. 54:1994;159-170.
34. 8-tetrahydro-cannabinol-dimethylheptyl-induced catalepsy in male rats. Neuroreport. 5:1994;761-765.
35. Rodríguez de Fonseca F., Villanúa M.A., Muñoz R.M., San-Martin-Clarke O., Navarro M. Differential effects of chronic treatment with either dopamine D1 or D2 receptor agonists on the acute neuroendocrine actions of the highly potent synthetic cannabinoid HU-210 in male rats. Neuroendocrinology. 61:1995;714-721.
36. 37] CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist (-)-11-hydroxy-Δ9-tetrahydrocannabinol-dimethylheptyl on defensive-withdrawal behavior in rats. J. Pharmacol. Exp. Ther. 276:1996;56-64.
37. Rodríguez de Fonseca F., Carrera M.R.A., Navarro M., Koob G.F., Weiss F. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science. 276:1997;2050-2054.
38. Romero J., García L., Ramos J., Fernández-Ruiz J.J. The putative cannabinoid receptor ligand, anandamide, stimulates hypothalamic tyrosine hydroxylase activity and inhibits prolactin release. Neuroendocrinol. Lett. 16:1994;159-164.
39. Steger R.W., De Paolo L.V., Asch R.H., Silverman A.Y. Interactions of delta-9-tetrahydrocannabinol with hypothalamic neurotransmitters controlling luteinizing hormone and prolactin release. Neuroendocrinology. 37:1983;361-370.
40. Tyrey L. Reversal of the delta-9-tetrahydrocannabinol inhibitory effect on prolactin secretion by rostral deafferentation of the medial basal hypothalamus. Neuroendocrinology. 44:1986;204-210.
41. 8-tetrahydrocannabinol-DMH. J. Pharmacol. Exp. Ther. 263:1992;1383-1390.
42. Venance L., Piomelli D., Glowinski J., Giaume C. Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes. Nature. 376:1995;590-594.
43. Weidenfeld J., Feldman S., Mechoulam R. Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinology. 59:1993;110-112.